Canada seeing highest percentage of positive flu tests in three seasons

Canada is recording the highest influenza test positivity in three seasons, with national positivity at 27.7% for the week ending Dec. 13 (Ontario 33.8%) and pediatric positivity at 73.3%. H3N2 is dominant, accounting for 71% of detected infections, and flu-associated hospitalizations rose from 2.1 to 3.6 per 100,000; three children aged five to nine died of influenza complications in the Ottawa region in December. Public health officials and clinicians warn of a potentially more severe season and urge vaccination despite reduced vaccine effectiveness against H3N2, a development likely to raise near-term healthcare utilization and staffing pressures but with limited broad market impact.

Analysis

Market structure: Short-term winners are vaccine manufacturers and retail pharmacies (seasonal vaccine doses, OTC cold/flu sales) while outpatient clinics and hospitals face revenue upside but margin compression from staffing/overtime. Expect a 5–15% seasonal lift in retail pharmacy traffic over the next 6–10 weeks versus baseline; diagnostic test vendors see volume spikes that boost CPM and revenue recognition in the coming 30–90 days.

Risk assessment: Tail risks include a larger-than-expected H3N2 wave driving hospitalization rates above 5 per 100,000 (current 3.6/100k), prompting localized school/work closures and material demand shocks to travel/leisure and regional labour supply; regulatory risks include emergency vaccine procurement changes or export controls. Time horizons: immediate (days–weeks) for testing and OTC sales, short-term (weeks–months) for vaccine revenue and hospital earnings, long-term (quarters) for potential policy shifts or durable behaviour change.

Trade implications: Favor short-dated directional exposure to diagnostics and pharmacies (call spreads) and selective long exposure to major flu-vaccine players (GSK, SNY) for Q1 2026 revenue; underweight airlines/hospitality for 4–8 weeks if absenteeism leads to softer holiday travel. Use relative-value: long CVS (CVS) vs short Mall/department store retail (M) to capture differential foot-traffic resilience; hedge insurer exposure (UNH) if hospitalization trends breach thresholds.

Contrarian angles: Consensus assumes vaccine efficacy is weak and will push all healthcare names higher; that may be overdone—H3N2 seasons historically boost vaccine volumes but not net profit margins for big pharmas more than 3–7%. If hospitalization growth stalls or schools remain open, diagnostic/test demand will mean-revert quickly; this creates mispricings in high-volatility small-cap diagnostic names (QDEL) where short-term premiums collapse once weekly positivity falls below 20%.

Key Decisions for Investors

• Establish a 2–3% portfolio long in large flu-vaccine exposed names: buy GSK (GSK) and Sanofi (SNY) equally weighted, implemented via 3-month 1:2 call spreads (buy ATM, sell 10–15% OTM) to capture seasonal uptick into Mar 2026; close if national H3N2 share drops below 50% or weekly hospitalization rate falls to ≤2.5/100k.
• Initiate a 2% long position in CVS Health (CVS) funded by a 1% short in Macy’s (M) or other mall retailers; rationale: vaccine and OTC sales lift pharmacy same-store traffic for 6–10 weeks — take profits if pharmacy foot traffic data or CVS weekly comps fall below +3% vs prior-year.
• Buy short-dated (30–90 day) call spreads on Quidel (QDEL) or Abbott (ABT) sized 0.5–1% notional to exploit higher testing volumes; unwind if national percent-positive for influenza falls under 20% for two consecutive weeks.
• Purchase protection: buy 6-month UNH 2–3% notional puts or an equivalent tail hedge if weekly flu-associated hospitalization rate exceeds 5/100k (trigger) to protect against insurer claims shock and margin hits—close if rate reverts below 3/100k for two weeks.